Helical domains that mediate lipid solubilization and ABCA1-specific cholesterol efflux in apolipoproteins C-I and A-II∗

Loren E. Smith,* Jere P. Segrest,† and W. Sean Davidson1,∗

Department of Pathology and Laboratory Medicine,* University of Cincinnati, Cincinnati, OH; and Department of Medicine and Atherosclerosis Research Unit,† University of Alabama at Birmingham, Birmingham, AL.

Abstract Many of the apolipoproteins in HDL can elicit cholesterol efflux via ABCA1, a critical initial step in HDL formation. Recent work has indicated that omnipresent amphipathic helices play a critical role, and these have been studied intensively in the most common HDL protein, apolipoprotein (apo)A-I. However, little information exists about helical domain arrangement in other apolipoproteins. We studied two of the smallest apolipoproteins known to interact with ABCA1, human apoA-II and apoC-I, in terms of ability to reorganize phospholipid (PL) bilayers and to promote ABCA1-mediated cholesterol. We found that both proteins contained helical domains that were fast and slow with respect to solubilizing PL. ABCA1-mediated efflux required a minimum of a bihelical polypeptide comprised of at least one each of a slow and fast lipid reorganizing domain. In both proteins, the fast helix was located at the C terminus preceded by a slow helix. Helical placement in apoC-I was not critical for ABCA1 activity, but helix swaps in apoA-II dramatically disrupted cholesterol efflux, indicating that the tertiary structure of the longer apolipoprotein is important for the pathway. This work has implications for a more complete molecular understanding of apolipoprotein-mediated cholesterol efflux.—Smith, L. E., J. P. Segrest, and W. S. Davidson. Helical domains that mediate lipid solubilization and ABCA1-specific cholesterol efflux in apolipoproteins C-I and A-II. J. Lipid Res. 2013. 54: 1939–1948.

Supplementary key words amphipathic helix • apolipoprotein-mediated cholesterol efflux • tertiary structure

High-density lipoproteins (HDL) are a family of plasma particles composed primarily of phospholipids, cholesterol, and proteins known as apolipoproteins. For over half a century, it has been repeatedly demonstrated that high levels of plasma HDL-cholesterol (HDL-C) are associated with a reduced risk of cardiovascular disease (CVD), at least in large human populations (1, 2). However, therapies that substantially raise the level of plasma HDL-C, particularly those that work via inhibition of its catabolism (3, 4) have been disappointing with regard to CVD protection. This has focused attention on a better understanding of the process of HDL biogenesis, which may prove to be a more productive therapeutic target. The first step is the assembly of phospholipids and cholesterol with lipid-poor apolipoproteins produced in the liver and intestine. This is dependent on the plasma membrane protein ATP-binding cassette transporter A1 (ABCA1, recently reviewed in Ref. 5). Although abundant in tissues that produce apoA-I, ABCA1 also plays important roles in reverse cholesterol transport from the periphery to the liver, especially in cells, such as macrophages, with excess intracellular cholesterol. When this transporter is dysfunctional, such as in Tangier disease, the removal of excess cholesterol from sites like the arterial wall is impaired (6–9). Genetic ablation of ABCA1 in peripheral macrophages results in increased atherosclerosis in rodent models (10).

A variety of exchangeable apolipoproteins can mediate ABCA1-dependent cholesterol efflux, including apolipoprotein (apo)A-I, A-II, A-IV, C-I, C-II, C-III, and E, though they must be largely lipid-unassociated prior to the interaction (11). However, they lack a clear consensus sequence like those that mediate traditional receptor:ligand interactions, indicating that a more generalized structural feature is at play. Current consensus holds that this feature is the amphipathic α-helix, a motif common to all exchangeable

Abbreviations: CVD, cardiovascular disease; DMPC, dimyristoyl phosphatidylcholine; DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; DPPE, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine; FC, free cholesterol; HDL-C, HDL-cholesterol; NBD-OLPC, nitrobenzoxadiazole 1-oleoyl-2-[12-(7-nitro-2,1,3-benzoxadiazol-4-yl) amino] dodecanoyl]-sn-glycero-3-phosphocholine; OD, optical density; OD0, initial optical density; PL, phospholipid.

To whom correspondence should be addressed. e-mail: Sean.Davidson@UC.edu

The online version of this article (available at http://www.jlr.org) contains supplementary data in the form of one figure and one table.

Copyright © 2013 by the American Society for Biochemistry and Molecular Biology, Inc.

This article is available online at http://www.jlr.org
apoprotein. Indeed, a multitude of small synthetic helical peptides have been shown to promote ABCA1-specific cholesterol efflux from a variety of cell types, and many of these have been explored as potential therapeutics (12, 13). In addition, a significant amount of work has shown that helical features such as mean hydrophobicity, size of the hydrophobic face, and amino acids at helical junctions are important for this function (14). Other groups suggested that a linear array of acidic amino acids aligned along the junction of the hydrophobic and hydrophilic faces of two amphipathic α-helices is a critical element for this process (15). However, peptides designed around cholesterol efflux have not yet fulfilled the promise of producing a robust therapeutic for CVD (16, 17). One reason for this could be that small synthetic peptides lack elements present in the full-length apolipoproteins that are required for subsequent HDL particle maturation and metabolism. Unfortunately, our understanding of the tertiary arrangement of these helical domains in the larger context of full-length apolipoproteins remains incomplete, with the most information limited to apoA-I. Given the large number of apolipoproteins that can access cellular lipid via ABCA1, it should be possible to identify common tertiary structural features within this family that mediate not only the lipid accumulation steps but also subsequent particle maturation. Such knowledge would add to our understanding of the physiological mechanism of HDL biogenesis, and may open new ways to modulate HDL levels at the biosynthesis end of its lifecycle.

Here, we began to address this problem by studying two of the smallest apolipoproteins known to interact with ABCA1, apoC-I and apoA-II. Their small size allowed the facile synthesis of significant domains within each protein, with the aim of identifying minimal structural features that mediate the reorganization of phospholipid surfaces and functional interaction with ABCA1. This led to the identification of a common bihelical structural motif and a more complete understanding of how these elements are arranged in the primary structure of human apolipoproteins.

MATERIALS AND METHODS

Reagents and cell lines

Dulbecco’s Modified Eagle Medium (DMEM) and fetal bovine serum (FBS) were acquired from Invitrogen (Carlsbad, CA). [1,2-3H(N)]cholesterol was supplied by Amershams Biosciences (Piscataway, NJ), 8-bromoadenosine 3′,5′-cyclic monophosphate sodium salt (cAMP) and gentamicin were purchased from Sigma (St. Louis, MO). The RAW264.7 macrophages used in the cholesterol efflux assay were obtained from the American Type Culture Collection (Manassas, VA) and were maintained in DMEM supplemented with 10% FBS and 10 μg/ml gentamicin. Radiolabeling and efflux measurements were performed in DMEM supplemented with 0.2% fatty-acid free BSA (Calbiochem, Gibbstown, NJ). 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) was purchased from Avanti Polar Lipids (Birmingham, AL). Human plasma apoC-I was purchased from Athens Research and Technology (Athens, GA). The apoC-I pMal-c2 vector was a generous gift from the Howlett Laboratory of the University of Melbourne, Victoria, Australia. All other reagents were the highest quality available.

Expression of apoC-I point mutants

Human mature apoC-I was generated in an E. coli expression system similar to those we have used to produce other recombinant apolipoproteins (18) using the pMal-c2 expression vector as described by Atcliffe et al. (19). Briefly, the apoC-I was expressed with an N-terminal maltose-binding protein tag, which was used for batch purification on an amylose affinity resin and eluted with free maltose. The affinity tag was cleaved using factor Xa protease. Separation of tag from protein was accomplished by separation on a Superdex 75 (GE Healthcare) gel filtration column in 3.5 M guanidine HCl to prevent aggregation of the protein. The recombinant apoC-I was over 95% pure as determined by Tris/tricine SDS-PAGE analysis. Circular dichroism spectroscopy measurements showed that the spectra of our recombinant apoC-I and plasma-isolated apoC-I are superimposable, with two minima at 208 and 222 nm, indicating that the secondary structure of the recombinant protein is predominantly α-helical proteins and similar to the plasma form (data not shown).

Peptide synthesis

ApoC-I- and apoA-II-based peptides were synthesized by GenScript Corp. (Scotch Plains, NJ), 21st Century Biochemicals (Marlboro, MA), or Peptide 2.0 (Chantilly, VA) and were acetylated on the N terminus and amidated on the C terminus. All peptides were greater than 95% pure as determined by high performance liquid chromatography. Peptides were stored lyophilized at −80°C until use. When needed, peptides were solubilized in ultrapure water ± 3M guanidine, then dialyzed into Standard Tris Buffer (STB, 10 mM Tris HCl, 150 mM NaCl, 1 mM EDTA, 0.02% sodium azide, pH 7.4), and stored under N2 until use. Secondary structure content was estimated by circular dichroism spectroscopy on a Jasco J-715 spectropolarimeter. Samples were dialyzed into 20 mM phosphate buffer (pH 7.4) and diluted to a concentration of 100 μg/ml. A background scan of phosphate buffer was subtracted from each sample scan. Plasma apoA-II from normolipidemic patients was isolated and purified as previously described for apoA-I (20).

DMPC liposome clearance assay

Peptides or plasma proteins were added to DMPC liposomes at the specified mole lipid:mole α-helix ratio, and the absorbance of the solution at 325 nm was recorded every 30 s for 20 min. Samples were measured in triplicate, and absorbances were averaged. The data were expressed as a normalized optical density (OD), which was calculated by dividing the sample OD by the initial OD (OD0). Two trials were measured on different days using fresh preparations of liposomes for each set of peptides. All measurements were made on an Amersham Biosciences Ultraspec 4000 UV/Visible spectrophotometer within a temperature-controlled cuvette at 24.5°C.

Free cholesterol efflux assay

RAW 264.7 macrophages were grown to 80% confluency, then incubated with media containing 1.0 μCi/ml [1,2-3H(N)]cholesterol for labeling ± 0.3 mM cAMP. In these cells, the presence of cAMP leads to expression of ABCA1 on the cell surface (21). After washing away any radiolabel not internalized by the cells, media containing the peptide or plasma protein of interest ± 0.3 mM cAMP were incubated with the cells for 8 h. At the beginning of this incubation, a t0 control plate was washed with PBS, and the
labeled cells in each well were dissolved in isopropanol. This solution was then dried under air, resolubilized in toluene, mixed with scintillation fluid, and counted on a 1900CA Packard liquid scintillation analyzer to determine the total amount of labeled cholesterol internalized by the cells at the beginning of the efflux experiment. After 8 h, a sample of media was filtered to remove floating cells and debris and then counted to determine how much labeled cholesterol was transferred to the peptide or plasma protein in the media during the incubation. Each protein or peptide was tested in triplicate, and the percentage efflux calculated was the average. Percentage efflux is the counts in the media divided by the total internalized counts per well calculated using the t₀ control plate, with background efflux to STB subtracted. The percentage efflux of each peptide was compared with baseline using a two-tailed Student t-test, with P < 0.05 indicating an ability of the peptide to stimulate free cholesterol (FC) efflux. For each set of peptides, at least two independent assays were performed using cells prepared on separate days.

RESULTS

Role of a linear array of acidic residues in apoC-I in the reorganization of phospholipid liposomes and ABCA1-mediated cholesterol efflux

Natarajan et al. (15) identified an evolutionarily conserved linear array of three acidic amino acid residues spanning helices 9 and 10 of human apoA-I that appeared to be required for promotion of ABCA1-mediated cholesterol efflux, at least in peptides derived from apoA-I. Our analysis of the primary structure of apoC-I (Fig. 1) identified a similar array of four glutamic acid residues (residues 33, 40, 44, and 51) spanning both putative helical domains of the protein (see Fig. 3A for the sequence of apoC-I) that were in a similar orientation relative to the nonpolar face as the peptides studied by Natarajan et al. To determine the importance of this array in the context of apoC-I, we systematically reversed the charge at each position by replacing the resident Glu with a basic Lys residue using our E. coli-based expression system. Because the ability to promote ABCA1-mediated cholesterol efflux has been linked to the ability to solubilize phospholipid bilayers (22, 23) (see Discussion), we first tested the ability of these mutants to spontaneously reorganize DMPC liposomes. Preliminary experiments demonstrated that apoC-I isolated from human plasma and the recombinant form generated in the bacterial system performed comparably in this assay (supplementary Fig. 1A). In this analysis, the protein or peptide of interest is added to turbid DMPC liposomes at the lipid gel-to-liquid crystal transition temperature, and the binding and emulsification of the lipid by the protein is indicated by a decrease in the solution turbidity as the peptides reorganize the liposomes into small lipoproteins. Fig. 2A shows that WT apoC-I was efficient at reorganizing the liposomes under these conditions, clearing the liposomes completely in about 10 min. ApoC-I E33K and apoC-I E51K were slightly more effective than WT, while apoC-I K40K was slightly less effective. In all cases, the differences from the WT protein were small compared with other apolipoprotein mutants we have studied in the past (24) and probably do not represent biologically relevant differences.

We next evaluated the point mutants for their ability to promote ABCA1-mediated cholesterol efflux. Again, we verified that the human plasma and recombinant forms of apoC-I performed comparably in the assay (supplementary Fig. IB), and concentration experiments showed that cholesterol efflux saturates above ~15 µg/ml under these conditions (not shown). Therefore, we tested the mutants at a concentration of 5 µg/ml to avoid obscuring any differences due to efflux saturation. The cholesterol efflux results are shown in Fig. 2B. In the absence of cAMP, the efflux of radiolabeled cholesterol to WT apoC-I was minimal, but this increased to about 11% in the presence of cAMP, reflecting the activity of induced ABCA1 (21). The apoC-I mutants E33K, E40K, and E44K were similar to WT. ApoC-I E51K exhibited a statistically lower degree of cholesterol efflux, but this effect was again small. Further mutations that introduced dual charge reversions at these sites also failed to produce significant effects on either DMPC clearance or ABCA1-mediated cholesterol efflux (not shown). Thus, the data suggest that this linear array of acidic amino acids is not a critical motif for mediating ABCA1 lipid efflux, at least in apoC-I. We were unable to detect a similar acidic array in apoA-II, further arguing that it is not a universal feature mediating ABCA1-mediated lipid efflux.

Design of peptides modeling the individual α-helices of apoC-I and apoA-II

To further examine human apoC-I and apoA-II for important structural elements with respect to ABCA1-mediated efflux, we synthesized short peptides representing each individual α-helix within these apolipoproteins. The determinations of the beginning and end of each α-helix in apoC-I are based on the analyses of Gursky et al. (25), who determined helices of lipid-free apoC-I with proline scanning and circular dichroism measurements, Rozek...
ing the protein with the PredictProtein program (29), observing the proline punctuation within apoA-II, model- and combining these findings with the sequence analysis and exchangeable apolipoproteins (28). The sequences of the 22 amino acids in length as observed in a wide range of putative helical character and were Putative helical breakpoints were favored if they resulted in a peptide with strong amphipathic character and were expected to clear DMPC liposomes and promote ABCA1-mediated cholesterol efflux. (A) ApoC-I was added to DMPC liposomes at a lipid:protein mass ratio of 2.5:1 at the DMPC gel to liquid-crystal phase transition at temperature of 24.5°C. As the apolipoprotein binds to and reorganizes the lipid, the liposomes are solubilized to lipoprotein discs and therefore scatter less light over time. For each sample, the light scattering at time 0 min was normalized to 1.0, and each subsequent reading was expressed as a fraction (OD divided by OD0). Filled circles, WT recombinant apoC-I; open circles, apoC-I E33K; filled triangles, apoC-I E40K; open triangles, apoC-I E44K. The experiments were repeated three times on separate days and the average values are plotted ± 1 sample SD. (B) RAW mouse macrophages were exchange-labeled with tritiated cholesterol and then treated with or without 8-Br-cAMP to upregulate ABCA1 expression as described in Methods. Each apolipoprotein (5 μg/ml) was then incubated with the cells for 8 h with or without 8-Br-cAMP, and the radioactivity appearing in the media was assessed by scintillation counting. The data are expressed as the percentage of label present in the cells immediately before the incubation period (T = 0 h). Black bars show cholesterol efflux in the absence of cAMP (ABCA1 independent), while the shaded bars show cholesterol efflux in the presence of cAMP (ABCA1 component). The experiment was run in triplicate and expressed as averages ± 1 sample SD. *P < 0.05 compared with WT apoC-I (two-tailed Student t-test).

et al., who used NMR on lipid-bound apoC-I to estimate helices (26), and Segrest et al. (27), who used sequence analysis to delineate helical regions within lipid-free apoC-I. Putative helical breakpoints were favored if they resulted in a peptide with strong amphipathic character and were 22 amino acids in length as observed in a wide range of exchangeable apolipoproteins (28). The sequences of the apoC-I peptides are shown in Fig. 3A. In a similar manner, by observing the proline punctuation within apoA-II, modeling the protein with the PredictProtein program (29), and combining these findings with the sequence analysis of lipid-free apoA-II by Segrest et al. (27), designations for apoA-II helical peptides were obtained (Fig. 3B). Due to some ambiguity in determining the boundaries of apoA-II helix 2, we produced a short form (residues 38–53, called apoA-II helix 2) and a long form (residues 32–50, apoA-II helix 2-long) to ensure that any functional differences were not due to inappropriate truncation. We found that the long form was functionally identical to the shortened peptide in both PL reorganization and cholesterol efflux (data not shown), and therefore, we refer to the short form throughout this article. All peptides were N-terminally acy- lated and C-terminally amidated to aid in helical formation in solution, as previously described (30).

Ability to reorganize phospholipid surfaces

For these experiments, each helix of apoC-I was compared with human plasma-isolated apoC-I on an equi- molar helical basis (i.e., 2:1 molar ratio; the same number of putative a-helical domains was present in each sample solution). Similarly, each helix of apoA-II was compared with human plasma-isolated apoA-II on an equimolar helical basis. Fig. 4A confirms the results shown in Fig. 2A, indicating that apoC-I rapidly cleared DMPC liposomes within about 10 min under these conditions. By contrast, apoC-I helix 1 failed to significantly modify liposome light scattering, exhibiting a similar clearance profile to DMPC liposomes incubated with buffer alone (not shown). This indicates that this helix either (i) failed to bind to the lipids or (ii) was able to bind the liposomes but was unable to rearrange the bilayer structure to smaller particles. ApoC-I helix 2 however, exhibited markedly increased clearance, with the reaction being effectively complete by the second time point (1 min). These data suggest that the majority of the ability of intact apoC-I to bind liposomes lies in its C-terminal helix. Fig. 4B shows a similar distribution of lipid-binding abilities among the helices of apoA-II. Whereas intact apoA-II was effective, apoA-II helix 2 was largely ineffective (as was the long form). However apoA-II helix 3 and apoA-II helix 5 were both more effective than the WT protein. These data indicate that (i) both apolipoproteins contain helices which are capable of “fast” lipid clearance and those which are incapable or “slow”; (ii) both apolipoproteins have a fast lipid-binding helix present at the C terminus of the mature protein; and (iii) the N-terminal helix in each protein can be either fast or slow. Gel filtration analysis showed that the particles produced by the individual peptides of both apoC-I and apoA-II generated peptide/lipid complexes that were generally consistent in size with those generated by the native apolipoprotein, although the size distributions were much broader in the case of the peptides (not shown).

We noted that the isolated fast lipid-binding helices studied above were all significantly more effective than the intact protein when tested at an equimolar helical concentration. In the case of apoC-I, it appears that the presence of at least one slow helix in combination with a fast helix may act as a brake on lipid binding/reorganization. To determine whether this is the case with the helical domains of apoA-II, two bihelical peptides were synthesized representing two naturally occurring pairs of fast emulsifying and nonemulsifying helices in apoA-II, apoA-II helix 1+2 (which spanned residues 8–53 of the mature sequence),
Helical requirements for ABCA1 lipid efflux

and apoA-II helix 2-3 (which spanned residues 38-73) (see Fig. 3). Fig. 5 shows that, despite some experimental variation, apoA-II helix 1+2 cleared lipid at a rate approximately similar to WT apoA-II, but much more slowly than apoA-II helix 1 by itself (Fig. 4B). Similarly, apoA-II helix 2-3 cleared lipid like WT apoA-II, but it was not as extreme as helix 3 in isolation. This indicates that the presence of a slow lipid-binding helix can attenuate the lipid reorganizing properties of a fast helix. We also determined whether this is a cooperative phenomenon by comparing the effect of incubating a mixture of the individual helices. We compared the clearance rates of apoC-I to an equimolar mixture of apoC-I helix 1 and apoC-I helix 2 (mixed as separate peptides). We also compared mixtures of appropriate helices in isolation to the bihelical peptides shown in Fig. 5. In all cases, the peptide mixtures cleared lipid faster than the corresponding bihelical peptide (i.e., similar to that for the fast helix in isolation) (not shown). This indicates that helices must be connected in order for the slow helix to attenuate the action of the fast helix.

**ABCA1-mediated FC efflux**

We next evaluated the ability of each helix in apoC-I and apoA-II to promote ABCA1-mediated cholesterol efflux. Again, individual helices were compared with plasma proteins on an equimolar α-helical basis at subsaturating concentrations. Fig. 6A demonstrates that neither apoC-I helix can serve as an efficient acceptor of cholesterol from ABCA1, although the intact protein was functional. Fig. 6B shows that the same is true for the individual helices of apoA-II, with the intact protein also exhibiting activity. This suggests that neither a fast lipid-emulsifying helix nor a nonlipid-emulsifying helix is sufficient for cholesterol efflux via ABCA1 when present in isolation.

In previous studies using synthetic apoA-I mimetic peptides, Sethi et al. (31) postulated that the minimal structural element for ABCA1 cholesterol acceptors is a pair of helices, with one being a fast emulsifier and one slow. This is consistent with our observation that intact apoC-I (essentially a single helix) was functional while its individual fast or slow helices were not. To test this in the context

---

**Fig. 3.** Synthetic peptides reflecting individual helical domains of apoC-I and apoA-II. (A) Full-length sequence of human mature apoC-I. Consensus helical domains based on sequence analyses are indicated, as are two bihelical constructs. The first simply reverses the order of the helices in the WT sequence (maintaining a predicted turn sequence KQSE between the helices), while the second completely reverses the amino acid order of the WT protein. The orientations of the helices in these two mutants with respect to the WT protein are shown by the black arrows under the sequences. (B) Full-length sequence of human mature (monomeric) apoA-II. Consensus helical domains based on several sequence analyses (see text) are shown in red, blue, and green, with correspondingly colored bars above. Individual peptides designed to mimic each individual helix (including two possibilities for helix 2) are aligned under the sequence. The sequence of two bihelical constructs is also shown.
failed to promote significant cholesterol efflux (Fig. 7). Interestingly, apoA-I helix 2+3, which has a fast lipid-binding helix at its C terminus, could promote ABCA1-mediated cholesterol efflux, although not as effectively as full-length apoA-II (Fig. 7). This supports the idea that at least two helices are required for specific cholesterol efflux via ABCA1, with a poor and fast lipid-emulsifying helix arranged N to C, respectively.

To further test the requirement of an N to C distribution of the slow and fast helices, we generated a series of helical swap constructs. In apoC-I, we reversed the position of helices 1 and 2 within the context of the full-length protein (ApoC-I helix 2+1, Fig. 3). This placed the fast helix on the N-terminal side and the slow helix at the C-terminal side, but kept each helix in otherwise the same orientation with respect to the dipole moment of the molecule. Fig. 8A shows that ApoC-I helix 2+1 was actually slightly more effective than WT apoC-I at promoting cholesterol efflux. We also tested a variant called ApoC-I reverse (essentially WT apoC-I synthesized backward). This has the effect of placing helix 1 at the C terminus and helix 2 at the N terminus like ApoC-I helix 2+1, but the sequence is reversed in relation to each helical dipole. This peptide also promoted cholesterol efflux with an efficiency comparable to WT apoC-I. Thus, the N- to C-terminal orientation of the fast and slow helices did not appear to be a major factor in determining ABCA1 cholesterol efflux in apoC-I.

Unlike in apoC-I, reversing the helical order in the apoA-II bihelical peptides completely abolished ABCA1-mediated cholesterol efflux. Fig. 7A shows that ApoA-II helix 2+3 exhibited partial efflux activity compared with WT apoA-II. However, ApoA-II helix 3+2, which has its fast and slow helices arranged N to C, was nonfunctional. ApoA-II helix 1+2, like ApoA-II helix 2+1, was also nonfunctional.

**DISCUSSION**

A popular model for the apolipoprotein-mediated removal of cellular lipids (32) holds that lipid-free (or lipid-poor) apolipoproteins interact with ABCA1 and stabilize its presence at the cell surface. This is consistent with prior studies showing that apoA-I can be cross-linked to ABCA1 and that apoA-I binding can prolong the residence of ABCA1 at the cell surface (33–35). Sustained lipid fl oprase activity by ABCA1 promotes the binding of apolipoproteins, via their amphipathic helices, to specific lipid sites on the plasma membrane. Nascent HDL particles are then formed by microsolubilization of membrane lipids. There is no specific apolipoprotein consensus sequence that mediates this process, and our experiments show that even relatively specific features, such as the linear array of acidic residues identified by Natarajan et al. (15), were not critical for either DMPC reorganization or ABCA1-mediated cholesterol efflux, at least in the case of apoC-I (Fig. 2). At this point, it can be stated that apolipoproteins that work through ABCA1 share the following features: 1) their sequences contain 11 and 22 mer amphipathic helices that

![Fig. 5](image-url)  
**Fig. 5.** Ability of bihelical peptides derived from the sequence of apoA-II to clear DMPC liposomes. Bihelical peptides modeling both potential helical pairings within apoA-II were added to DMPC liposomes at a 10 mol lipid:1 mol α-helix ratio, with the peptides added at an equimolar helical concentration as apoA-II. Conditions and data treatment for both panels were as indicated in Fig. 1. All points are the mean of three replicates, and bars represent mean ±1 sample SD.

![Fig. 6](image-url)  
**Fig. 6.** ABCA1-dependent efflux of cholesterol to lipid-free plasma proteins and individual helical peptides. (A) Cholesterol efflux to lipid-free human plasma apoC-I and individual C-I helical peptides. The experiment was performed as in Fig. 1, except that the human plasma apoC-I was at 5 µg per ml and the individual helices were present at the same molar helix concentration. (B) Cholesterol efflux to lipid-free human plasma apoA-II and individual A-II helical peptides. The human plasma apoA-II was present at 5 µg per ml and the individual helical peptides were present at the same molar helix concentration. Bars represent mean ± 1 sample SD of three replicates. Black bars represent the absence of cAMP, and gray bars represent the presence of cAMP.
Helical requirements for ABCA1 lipid efflux

...
domain at its C terminus that likely does not form an amphipathic helix (48). Furthermore, our studies have shown that the critical apoA-IV lipid-binding elements occur near its N terminus, in sharp contrast to the others discussed above. Interestingly, our recent crystal structural analysis of apoA-IV (49) and comparisons with the crystal structure of the highly related apoA-I (50) provide intriguing hints that apoA-IV may have undergone a gene reversion event sometime in its evolution from a common ancestor apolipoprotein (51). Indeed, many structural features that appear at the N terminus of apoA-I appear in the C-terminal aspects of apoA-IV. Thus, the unique tertiary architecture of apoA-IV is likely permissive to a lipid-binding helical domain present near the N terminus.

Another outcome of this study is that apolipoproteins that successfully promote ABCA1-mediated cholesterol efflux contain mixture of at least one each of a fast and a slow lipid-binding helix. ApoC-I could only promote cholesterol efflux when both slow and fast helices were present and only when those two helices were physically connected in the same peptide. Similarly, in apoA-II, the individual helical domains were not able to promote ABCA1-mediated lipid efflux despite avid DMPC clearance. However, helices 2 (slow) and 3 (fast) were active when present in the same bipherical peptide (Fig. 7). The observation that all ABCA1-competent constructs contained at least one poor and one fast lipid-binding helix suggests that the combination is important during the pathway. The addition of helix 9 (an 11 mer with low lipid affinity) to the strong lipid-binding helix 10 in apoA-I increases the specificity of the peptide for ABCA1-mediated cholesterol efflux (i.e., it reduces the ability of helix 10 alone to non-specifically solubilize membrane lipids, leading to cellular toxicity) (15). Sethi et al. (31) clearly demonstrated that asymmetry with respect to lipid binding among the helices in synthetic bipherical peptides improves the specificity of ABCA1-mediated lipid efflux. They suggested that the poor lipid-binding helix acts as a check on the lipid affinity of the fast helix, thus preventing nonspecific or detergent-like removal of membrane lipids. In such case, ABCA1 becomes necessary to overcome energy barriers to allow the apolipoprotein to accumulate lipid. In our study, we did not notice an overly toxic effect of our individual helical peptides on the RAW macrophages. For example, apoA-2 helix 3 and apoC-I helix 2 in isolation were highly effective phospholipid “detergents” (Fig. 4), but they did not promote detergent-like lipid removal in our system, as evidenced by the minimal levels of cholesterol efflux in control cells that were not treated with cAMP (Fig. 6). It may be that two fast PL-solubilizing domains are required for the cytotoxic effect (31). The poor lipid-binding helix may play a role in the ABCA1 pathway in addition to preventing cell toxicity, perhaps mediating intermolecular interactions among the apolipoprotein monomers as the particle is being assembled. Alternatively, the poor lipid-binding helix may physically tether the pair close to the surface of the lipid bilayer. This controlled submersion of the lipid-binding helix could facilitate the microsolubilization process. Of note, Swiridov et al. (52) recently showed that the presence of high volume hydrophobic residues (tryptophan and phenylalanine) near the hinge between two helical domains was important for lipid solubilization and ABCA1-mediated cholesterol efflux in the synthetic peptide 5A. However, inspection of Fig. 3 shows that the helical connection regions in apoC-I and A-II are devoid of these residues, suggesting that other factors are at play in these native apolipoproteins.

In summary, this article adds two apolipoproteins to our knowledge base in terms of the individual contributions of their amphipathic helical domains to the process of phospholipid reorganization/microsolubilization and ABCA1-mediated cholesterol efflux. The evidence shows a common organizational theme among most exchangeable apolipoproteins that includes the presence of an avid lipid-binding domain situated at a usually conformationally dynamic C terminus. The relationship of this avid domain to other lower affinity domains appears to dictate whether the protein can engage the ABCA1 pathway for lipid efflux. Further studies on the role of these domains in other steps of the pathway, including stabilization of cell surface ABCA1 and HDL particle maturation, will be helpful in delineating the molecular details of ABCA1-mediated cholesterol efflux and HDL biogenesis.

The authors thank Dr. Apryl Stalcup, Department of Chemistry, University of Cincinnati, for generous donation of time on her spectropolarimeter.

REFERENCES

1. Gordon, T., W. P. Castelli, M. C. Hjortland, W. B. Kannel, and T. R. Dawber. 1977. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62:707–714.

2. Assmann, G., H. Schulte, A. vonEckardstein, and Y. D. Huang. 1996. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiologic implications for reverse cholesterol transport. Atherosclerosis. 124:S1–S20.

3. Barter, P. J., M. Caulfield, M. Eriksson, S. M. Grundy, J. J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. C. Tardif, D. D. Waters, et al. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357:2109–2122.

4. Schwartz, G. G., A. G. Olsson, M. Ahl, C. M. Ballantyne, P. J. Barter, J. Brumm, B. R. Chaitman, I. M. Holme, D. Kallend, L. A. Leiter, et al. 2012. Effects of dalceparib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367:2089–2099.

5. Yvan-Charvet, L., N. Wang, and A. R. Tall. 2010. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler. Thromb. Vasc. Biol. 30:139–145.

6. Rust, S., M. Rosier, H. Funke, J. Real, Z. Amoura, J. C. Piette, J. F. Deleuze, H. B. Brewer, N. Duverger, P. Denefle, et al. 1999. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22:352–355.

7. Bodziocioh, M., E. Orso, J. Klucken, T. Langmann, A. Botcher, W. Diederich, W. Drobnik, S. Barlage, C. Bachler, M. Porsch-Oscumarene, et al. 1999. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22:347–351.

8. Brooks-Wilson, A., M. Marcil, S. M. Clee, L. H. Zhang, K. Roomp, M. van Dam, L. Yu, C. Brewer, J. A. Collins, H. O. Molhuizen, et al. 1999. Mutations in ABCI in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22:336–345.

9. Lawn, R. M., D. P. Wede, M. R. Garvin, X. Wang, K. Schwartz, J. G. Porter, J. J. Seilheimer, A. M. Vaughan, and J. F. Oram. 1999.
The Tangier disease gene product ABCA1 controls the cellular apolipoprotein-mediated lipid efflux pathway. *J. Clin. Invest.* **104**: R25–R31.

21. Oram, J. F., R. M. Lawn, M. R. Garvin, and D. P. Wade. 2000.

20. Watson, C. E., N. Weissbach, L. Kjems, S. Ayalasomayajula, Y. Zhang, I. Chang, M. Navab, S. Hama, G. Hough, S. T. Reddy, et al. 2001. The interaction of human apolipoprotein C–I with sub-mi- crocalpain degradation and is reversed by ApoA-I. *Arterioscler. Thromb. Vasc. Biol.* **21**: 1603–1609.

19. Atcliffe, B. W., C. A. MacRaild, P. R. Gooley, and G. J. Howlett. 2008. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. *Adv. Protein Chem.* **83**: 303–369.

18. Tubb, M. R., L. E. Smith, and W. S. Davidson. 2009. Purification of recombinant apolipoproteins A-I and AIV and efficient affinity tag cleavage by tobacco etch virus protease. *J. Lipid Res.* **50**: 1497–1504.

17. Segrest, J. P., M. K. Jones, H. De Loof, C. G. Brouillette, Y. V. Venkatatalapahati, and G. M. Anantharamaiah. 1992. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. *J. Lipid Res.* **33**: 141–160.

16. Vedhachalam, C., A. B. Ghering, W. S. Davidson, S. Lund-Katz, G. H. Rothblat, and M. C. Phillips. 2007. ABCA1-mediated surface binding sites for ApoA-I. *Arterioscler. Thromb. Vasc. Biol.* **27**: 1603–1609.

15. Natarajan, P., T. M. Forte, B. Chu, M. C. Phillips, J. F. Oram, and J. K. Bielicki. 2004. Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1. *J. Biol. Chem.* **279**: 24044–24052.

14. Watson, C. E., N. Weissbach, L. Kjems, S. Avalasomayajula, Y. Zhang, I. Chang, M. Navab, S. Hama, G. Hough, S. T. Reddy, et al. 2011. Treatment of patients with cardiovascular disease with L-4F, an apo-AI mimic, did not improve selected biomarkers of HDL function. *J. Lipid Res.* **52**: 561–573.

13. Wool, G. D., C. A. Reardon, and G. S. Getz. 2008. Apolipoprotein-AI mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties. *J. Lipid Res.* **49**: 1268–1283.

12. Remaley, A. T., J. A. Stonik, S. J. Demosky, E. B. Neufeld, A. V. Bocharov, T. G. Vishnyakova, A. P. Patterson, N. J. Duverger, S. Santamaria-Bojo, et al. 2001. Apolipoprotein specificity for lipid efflux by the human ABCA1 transporter. *Biochemistry. Biophys. Res. Commun.* **280**: 818–823.

11. Remaley, A. T., T. F. Thomas, J. A. Stonik, S. J. Demosky, S. E. Bark, E. B. Neufeld, A. V. Bocharov, T. G. Vishnyakova, A. P. Patterson, T. L. Eggerman, et al. 2003. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. *J. Lipid Res.* **44**: 828–836.

10. Remaley, A. T., R. M. Lawn, M. R. Garvin, and D. P. Wade. 2000. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. *Arterioscler. Thromb. Vasc. Biol.* **20**: 630–637.

9. Wool, G. D., C. A. Reardon, and G. S. Getz. 2008. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties. *J. Lipid Res.* **49**: 1268–1283.

8. D’Souza, W. J., J. A. Stonik, A. Murphy, S. J. Demosky, A. A. Sethi, X. L. Moore, J. Chin-Dusting, A. T. Remaley, and D. Sviridov. 2010. Structure/function relationships of apolipoprotein a4 mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein. *Curr. Res. Rev.* **10**: 217–227.

7. Maiorano, and W. S. Davidson. 2002. The role of apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties. *J. Lipid Res.* **49**: 1268–1283.

6. Wool, G. D., C. A. Reardon, and G. S. Getz. 2008. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties. *J. Lipid Res.* **49**: 1268–1283.

5. Wool, G. D., C. A. Reardon, and G. S. Getz. 2008. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties. *J. Lipid Res.* **49**: 1268–1283.

4. Remaley, A. T., R. M. Lawn, M. R. Garvin, and D. P. Wade. 2000. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. *Arterioscler. Thromb. Vasc. Biol.* **20**: 630–637.

3. Wool, G. D., C. A. Reardon, and G. S. Getz. 2008. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties. *J. Lipid Res.* **49**: 1268–1283.

2. Remaley, A. T., T. F. Thomas, J. A. Stonik, S. J. Demosky, S. E. Bark, E. B. Neufeld, A. V. Bocharov, T. G. Vishnyakova, A. P. Patterson, T. L. Eggerman, et al. 2003. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. *J. Lipid Res.* **44**: 828–836.

1. Wool, G. D., C. A. Reardon, and G. S. Getz. 2008. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties. *J. Lipid Res.* **49**: 1268–1283.
45. Tanaka, M., P. Dhanasekaran, D. Nguyen, S. Ohta, S. Lund-Katz, M. C. Phillips, and H. Saito. 2006. Contributions of the N- and C-terminal helical segments to the lipid-free structure and lipid interaction of apolipoprotein A-I. Biochemistry. 45: 10351–10358.

46. Davidson, W. S., T. Hazlett, W. W. Mantulin, and A. Jonas. 1996. The role of apolipoprotein AI domains in lipid binding. Proc. Natl. Acad. Sci. USA. 93: 15605–15610.

47. Westerlund, J. A., and K. H. Weisgraber. 1993. Discrete carboxy-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. J. Biol. Chem. 268: 15745–15750.

48. Weinberg, R. B. 1994. Identification of functional domains in the plasma apolipoproteins by analysis of inter-species sequence variability. J. Lipid Res. 35: 2212–2222.

49. Deng, X., J. Morris, J. Dressmen, M. R. Tubb, P. Tso, W. G. Jerome, W. S. Davidson, and T. B. Thompson. 2012. The structure of dimeric apolipoprotein A-IV and its mechanism of self-association. Structure. 20: 767–779.

50. Mei, X., and D. Atkinson. 2011. Crystal structure of C-terminal truncated apolipoprotein A-I reveals the assembly of high density lipoprotein (HDL) by dimerization. J. Biol. Chem. 286: 38570–38582.

51. Karathanasis, S. K., P. Oettgen, I. A. Haddad, and S. E. Antonarakis. 1986. Structure, evolution, and polymorphisms of the human apolipoprotein A4 gene (APOA4). Proc. Natl. Acad. Sci. USA. 83: 8457–8461.

52. Sviridov, D. O., A. M. Andrianov, I. V. Anishchenko, J. A. Stonik, M. J. Amar, S. Turner, and A. T. Remaley. 2013. Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter. J. Pharmacol. Exp. Ther. 344: 50–58.

53. Segrest, J. P., M. K. Jones, V. K. Mishra, and G. M. Ananatharamaiah. 2002. Experimental and computational studies of the interactions of amphipathic peptides with lipid surfaces. In Peptide-Lipid Interactions. Vol. 52. S. A. Simon and T. J. McIntosh, editors. 391–429.